MX2020000332A - Preparacion que comprende vonoprazan. - Google Patents
Preparacion que comprende vonoprazan.Info
- Publication number
- MX2020000332A MX2020000332A MX2020000332A MX2020000332A MX2020000332A MX 2020000332 A MX2020000332 A MX 2020000332A MX 2020000332 A MX2020000332 A MX 2020000332A MX 2020000332 A MX2020000332 A MX 2020000332A MX 2020000332 A MX2020000332 A MX 2020000332A
- Authority
- MX
- Mexico
- Prior art keywords
- vonoprazan
- organic acid
- salt
- preparation
- acid salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención tiene por objeto proporcionar una preparación de la que se espera que mejore el sabor amargo de una sal de ácido orgánico de vonoprazán y permita una rápida disolución de la sal de ácido orgánico de vonoprazán después de la administración. La presente invención proporciona una preparación que contiene gránulos finos o gránulos que contienen una sal de ácido orgánico de vonoprazán, (2) una capa intermedia que contiene el mismo ácido orgánico que el ácido orgánico que forma la sal de vonoprazán en (1), o una de sus sales, y (3) una capa de recubrimiento que contiene un polímero insoluble en agua.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017135046 | 2017-07-10 | ||
PCT/JP2018/026416 WO2019013310A1 (en) | 2017-07-10 | 2018-07-09 | PREPARATION COMPRISING VONOPRAZAN |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020000332A true MX2020000332A (es) | 2020-07-13 |
Family
ID=63209641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020000332A MX2020000332A (es) | 2017-07-10 | 2018-07-09 | Preparacion que comprende vonoprazan. |
Country Status (16)
Country | Link |
---|---|
US (1) | US11696893B2 (es) |
EP (1) | EP3651735B1 (es) |
JP (1) | JP7228535B2 (es) |
KR (1) | KR20200026964A (es) |
CN (1) | CN110831579A (es) |
AR (1) | AR112269A1 (es) |
BR (1) | BR112020000318A2 (es) |
CA (1) | CA3069563A1 (es) |
CO (1) | CO2020000490A2 (es) |
EC (1) | ECSP20009533A (es) |
ES (1) | ES2921931T3 (es) |
MX (1) | MX2020000332A (es) |
PE (1) | PE20200442A1 (es) |
PH (1) | PH12020500068A1 (es) |
SG (1) | SG11202000136YA (es) |
WO (1) | WO2019013310A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109900822A (zh) * | 2019-03-12 | 2019-06-18 | 康诚科瑞医药研发(武汉)有限公司 | 一种血浆中沃诺拉赞的定量检测方法 |
CN110538153B (zh) * | 2019-09-26 | 2022-04-26 | 扬子江药业集团四川海蓉药业有限公司 | 一种高稳定性、快速释放的固体制剂及其制备方法 |
CN113633616A (zh) * | 2020-05-11 | 2021-11-12 | 鲁南制药集团股份有限公司 | 一种生物利用度高的固体制剂 |
US11767311B2 (en) | 2020-06-17 | 2023-09-26 | Ildong Pharmaceutical Co., Ltd. | Acid secretion inhibitor and use thereof |
CN111973565A (zh) * | 2020-07-07 | 2020-11-24 | 南京海纳医药科技股份有限公司 | 一种含有富马酸沃诺拉赞的片剂及其溶出度测定方法 |
CN112353802A (zh) * | 2020-11-26 | 2021-02-12 | 山东诚创蓝海医药科技有限公司 | 一种富马酸伏诺拉生掩味组合物及其应用 |
CN113390983B (zh) * | 2021-05-26 | 2022-06-07 | 株洲千金药业股份有限公司 | 一种同时测定富马酸伏诺拉生中3种杂质的检测方法 |
CN113827574A (zh) * | 2021-10-18 | 2021-12-24 | 沈阳药科大学 | 一种富马酸沃诺拉赞口腔速溶片及其制备方法 |
CN117503707A (zh) * | 2022-08-05 | 2024-02-06 | 哈尔滨市康隆药业有限责任公司 | 一种掩味微球及其制备工艺和应用 |
CN116966180B (zh) * | 2022-11-10 | 2024-05-14 | 山东道合药业有限公司 | 沃诺拉赞焦谷氨酸盐的片剂、注射剂、复方制剂 |
CN115721611A (zh) * | 2022-12-09 | 2023-03-03 | 北京斯利安药业有限公司 | 富马酸伏诺拉生干混悬剂及其制备方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH072761B2 (ja) | 1985-03-20 | 1995-01-18 | 不二パウダル株式会社 | 微結晶セルロ−ス球形顆粒及びその製造法 |
EP1787640A4 (en) | 2004-04-30 | 2012-04-11 | Astellas Pharma Inc | GRAINED PHARMACEUTICAL COMPOSITION WITH TEMPORARY DELIVERY FOR ORAL ADMINISTRATION AND FAST-DECREASING INTRAORAL TABLET WITH THE COMPOSITION |
ES2402362T3 (es) | 2004-09-30 | 2013-05-03 | Takeda Pharmaceutical Company Limited | Inhibidores de la bomba de protones |
ME00610B (me) | 2005-08-30 | 2011-12-20 | Takeda Pharmaceuticals Co | 1 –heterociklilsulfonil, 2 –aminometil, 5– (hetero–) aril supstituisan 1–h–pirol derivati kao inhibitori lučenja kiseline |
JP5228359B2 (ja) * | 2007-04-12 | 2013-07-03 | ニプロ株式会社 | 主薬粒子及びその製造方法ならびに口腔内崩壊錠 |
BRPI0820997A2 (pt) | 2007-12-10 | 2014-12-23 | Eurand Inc | Comprimidos de desintegração oral compreendendo difenidramina. |
US9186411B2 (en) | 2008-07-28 | 2015-11-17 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
PE20141174A1 (es) | 2008-08-27 | 2014-09-19 | Takeda Pharmaceutical | Compuestos de pirrol como inhibidores de la bomba de protones |
SG10201602311XA (en) * | 2010-12-27 | 2016-04-28 | Takeda Pharmaceutical | Orally disintegrating tablet |
US9487485B2 (en) | 2013-02-28 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Method for producing sulfonyl chloride compound |
MA41850A (fr) | 2015-03-31 | 2018-02-06 | Takeda Pharmaceuticals Co | Nouvelles utilisations pharmaceutiques |
EP3636283A1 (en) | 2015-06-04 | 2020-04-15 | Pfizer Inc | Solid dosage forms of palbociclib |
WO2017018473A1 (ja) | 2015-07-30 | 2017-02-02 | 武田薬品工業株式会社 | 錠剤 |
CN105030725B (zh) * | 2015-08-26 | 2019-12-10 | 迪沙药业集团有限公司 | 一种富马酸沃诺拉赞肠溶组合物及其制备方法 |
CN105030720B (zh) * | 2015-08-26 | 2019-12-10 | 迪沙药业集团有限公司 | 一种富马酸沃诺拉赞肠溶片及其制备方法 |
CN105663096B (zh) * | 2016-01-25 | 2019-06-14 | 南京济群医药科技股份有限公司 | 一种沃诺拉赞口腔速溶膜剂及其制备方法 |
JP2017135046A (ja) | 2016-01-29 | 2017-08-03 | 株式会社荏原製作所 | 検査装置 |
-
2018
- 2018-07-09 US US16/629,096 patent/US11696893B2/en active Active
- 2018-07-09 BR BR112020000318-2A patent/BR112020000318A2/pt unknown
- 2018-07-09 SG SG11202000136YA patent/SG11202000136YA/en unknown
- 2018-07-09 CA CA3069563A patent/CA3069563A1/en active Pending
- 2018-07-09 KR KR1020207003512A patent/KR20200026964A/ko not_active Application Discontinuation
- 2018-07-09 JP JP2019571547A patent/JP7228535B2/ja active Active
- 2018-07-09 ES ES18755569T patent/ES2921931T3/es active Active
- 2018-07-09 PE PE2020000031A patent/PE20200442A1/es unknown
- 2018-07-09 MX MX2020000332A patent/MX2020000332A/es unknown
- 2018-07-09 WO PCT/JP2018/026416 patent/WO2019013310A1/en unknown
- 2018-07-09 CN CN201880044629.2A patent/CN110831579A/zh active Pending
- 2018-07-09 EP EP18755569.3A patent/EP3651735B1/en active Active
- 2018-07-10 AR ARP180101913 patent/AR112269A1/es unknown
-
2020
- 2020-01-08 PH PH12020500068A patent/PH12020500068A1/en unknown
- 2020-01-16 CO CONC2020/0000490A patent/CO2020000490A2/es unknown
- 2020-02-07 EC ECSENADI20209533A patent/ECSP20009533A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP20009533A (es) | 2020-04-22 |
US11696893B2 (en) | 2023-07-11 |
CO2020000490A2 (es) | 2020-02-28 |
JP7228535B2 (ja) | 2023-02-24 |
CA3069563A1 (en) | 2019-01-17 |
EP3651735B1 (en) | 2022-04-13 |
TW201907919A (zh) | 2019-03-01 |
RU2020105670A (ru) | 2021-08-10 |
ES2921931T3 (es) | 2022-09-02 |
KR20200026964A (ko) | 2020-03-11 |
SG11202000136YA (en) | 2020-02-27 |
WO2019013310A1 (en) | 2019-01-17 |
US20200163881A1 (en) | 2020-05-28 |
AR112269A1 (es) | 2019-10-09 |
JP2020526486A (ja) | 2020-08-31 |
RU2020105670A3 (es) | 2021-10-26 |
EP3651735A1 (en) | 2020-05-20 |
PE20200442A1 (es) | 2020-02-28 |
CN110831579A (zh) | 2020-02-21 |
BR112020000318A2 (pt) | 2020-07-14 |
PH12020500068A1 (en) | 2020-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500068A1 (en) | Preparation comprising vonoprazan | |
IL245117A0 (en) | Co-crystals of (n - (s-methyl-8-(1((2'-methyl-['4,5-bipyrimidine]-6-yl)amino)propane-2-yl)quinoline-4-carboxamide, Derivatives modified by their deuterium, methods for their preparation, preparations containing them and their uses | |
WO2015165413A8 (zh) | 一种新型的稳定型抗体药物耦联物及其制备方法和用途 | |
MX2015012414A (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
WO2013129889A3 (ko) | 실데나필을 유효성분으로 함유하며 고미가 은폐된 고함량 속용필름 | |
EP3412292B8 (en) | Use of methoxatin, derivative and/or salt thereof in sjogren's syndrome and pharmaceutical composition | |
WO2017062468A8 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
MX2017000041A (es) | Formulaciones de liberacion inmediata disuasivas de abuso que comprenden polisacaridos no celulosicos. | |
WO2019108021A3 (ko) | 토파시티닙을 포함하는 약제학적 조성물 | |
MX2015017202A (es) | Formulacion de liberacion modificada. | |
AP2014007866A0 (en) | Water-soluble granule formulation of 2,4-D salt and preparation method thereof | |
TN2016000121A1 (en) | Cyclic thienouracil-carboxamides and use thereof | |
MX2015013155A (es) | Formulaciones farmaceuticas de la familia de la tetrandrina y metodo. | |
MX2019010228A (es) | Composición para liberación controlada de sustancias fisiológicamente activas y proceso para su preparación. | |
EP3295932A3 (en) | Stable odf composition containing hardly soluble therapeutic agent | |
WO2014144407A8 (en) | Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof | |
EP3648745A4 (en) | PHARMACEUTICAL COMPOSITION CONSISTING OF A MULTI-UNIT SPHEROIDAL TABLET CONTAINING ESOMEPRAZOLE AND A PHARMACEUTICAL SALT OF THE SAME, AND PROCESS FOR THE PREPARATION OF THE PHARMACEUTICAL COMPOSITION | |
WO2016093554A3 (ko) | 신규한 4-(아릴)-n-(2-알콕시티에노[3,2-b]피라진-3-일)-피페라진-1-카복스아미드 유도체 및 이의 항증식 효과 | |
PH12014502407A1 (en) | New alfentanil composition for the treatment of acute pain | |
SG11201902588PA (en) | N3-Cyclically Substituted Thienouracils And Use Thereof | |
EA201990129A1 (ru) | Таблетированный состав с улучшенным профилем растворения для лечения болезни паркинсона | |
MX2017004032A (es) | Composicion farmaceutica solida que comprende amlodipino y losartan. | |
JP2017008001A5 (es) | ||
EP3593805A4 (en) | USE OF A VITAMIN COMPOSITION IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION, TREATMENT OR DELAY OF ALZHEIMER'S DISEASE | |
WO2016091805A3 (de) | Naloxon-monopräparat und mehrschichttablette |